Hutchison China MediTech Announces Approval of Ayvadex® (Fanregratinib) for Treatment of FGFR2 Fusion/Rearranged Intrahepatic Cholangiocarcinoma Patients in China
August 28, 2026 — 10:40 CST
This Data Is Locked!
This area is available only to Subscribers.
Hutchison China MediTech, also known as HUTCHMED (NASDAQ/LSE: HCM; HKEX: 13), disclosed that the new drug application for Fanregratinib (HMPL-453) has received conditional approval from... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
